1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1159/000095338" target="_blank" rel="noreferrer noopener">http://doi.org/10.1159/000095338</a>
Pages
295–302
Issue
5
Volume
83
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Publisher
An entity responsible for making the resource available
Neuroendocrinology
Date
A point or period of time associated with an event in the lifecycle of the resource
2006
2006
Subject
The topic of the resource
3; 4-Dihydroxyphenylacetic Acid/metabolism; Androgens/administration & dosage; Animals; Dopamine Agents/*administration & dosage/toxicity; Dopamine/metabolism; Dose-Response Relationship; Drug; Drug Administration Schedule; Estradiol/administration & dosage/*analogs & derivatives/physiology; Estrogen Antagonists/administration & dosage; Female; Methamphetamine/*administration & dosage/toxicity; Mice; Neostriatum/*drug effects/metabolism; Nerve Degeneration/chemically induced/prevention & control; Neuroprotective Agents/administration & dosage; Neurotoxins/*administration & dosage; Ovariectomy; Parkinson Disease/physiopathology; Substantia Nigra/*drug effects/metabolism; Tamoxifen/administration & dosage
Creator
An entity primarily responsible for making the resource
Liu Bin; Dluzen Dean E
Description
An account of the resource
Estrogen increases methamphetamine (MA)-induced neurotoxicity within the impaired nigrostriatal dopaminergic (NSDA) system of ovariectomized female mice, as defined by enhanced striatal dopamine (DA) depletion. In this study we compared the effects of a lower dose of estradiol benzoate (EB, 1 microg) with related agents–tamoxifen (TMX, 12.5 microg), testosterone (5 microg) and dehydroepiandrosterone (DHEA, 3 mg) in this paradigm. In experiment 1, ovariectomized mice received an initial treatment with MA. At 1 week after MA, mice were treated with EB, TMX, testosterone, DHEA or oil vehicle and 24 h later a second MA treatment. Striatal DA and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations in the MA-treated groups were decreased compared to the non-MA-treated control. Neither EB nor any of the other agents tested showed enhanced neurodegenerative or neuroprotective effects against a second MA invasion. To verify that estrogen was capable of showing a neuroprotective effect under a condition of two administrations of MA, in experiment 2, EB was administered either once or twice prior to each of the two MA treatments. EB treatment prior to the first MA invasion or first and second MA protected the NSDA system against DA and DOPAC depletion. These results imply that a lower dose of EB, TMX, testosterone and DHEA cannot exert neurodegenerative or neuroprotective effects in the impaired NSDA model. However, EB administered prior to the introduction of neurotoxicity can protect the NSDA system. This study may provide an understanding of the variations in results on the effects of estrogen upon the NSDA neurodegenerative disorder, Parkinson's disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1159/000095338" target="_blank" rel="noreferrer noopener">10.1159/000095338</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2006
3
4-Dihydroxyphenylacetic Acid/metabolism
Androgens/administration & dosage
Animals
Dluzen Dean E
Dopamine Agents/*administration & dosage/toxicity
Dopamine/metabolism
Dose-Response Relationship
Drug
Drug Administration Schedule
Estradiol/administration & dosage/*analogs & derivatives/physiology
Estrogen Antagonists/administration & dosage
Female
Liu Bin
Methamphetamine/*administration & dosage/toxicity
Mice
Neostriatum/*drug effects/metabolism
Nerve Degeneration/chemically induced/prevention & control
Neuroendocrinology
Neuroprotective Agents/administration & dosage
Neurotoxins/*administration & dosage
Ovariectomy
Parkinson Disease/physiopathology
Substantia Nigra/*drug effects/metabolism
Tamoxifen/administration & dosage
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3816/cbc.2001.s.004" target="_blank" rel="noreferrer noopener">http://doi.org/10.3816/cbc.2001.s.004</a>
Pages
S20–30
Volume
2 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer.
Publisher
An entity responsible for making the resource available
Clinical breast cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2001
2001-10
Subject
The topic of the resource
Female; Humans; Prognosis; Decision Making; Clinical Trials as Topic; Neoadjuvant Therapy; Tamoxifen/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Breast Neoplasms/*drug therapy/surgery; Diphosphonates/therapeutic use; Ovary/drug effects/physiology; Taxoids/therapeutic use; Antineoplastic Agents; Adjuvant; Chemotherapy; Hormonal/*therapeutic use
Creator
An entity primarily responsible for making the resource
Mamounas E P
Description
An account of the resource
In patients with operable breast cancer, adjuvant hormonal therapy and adjuvant chemotherapy result in significant and long-term reductions in the rates of disease recurrence and death. These reductions are evident in both patients with node-negative as well as in those with node-positive disease. However, several issues in the adjuvant treatment of breast cancer still remain unresolved. These issues were recently considered at the 2000 National Institutes of Health (NIH) Consensus Development Conference, which reviewed the current state of knowledge on adjuvant therapy and outlined strategies for future research. In the area of adjuvant hormonal therapy, tamoxifen is still the gold standard, and present evidence supports the use of tamoxifen for patients with estrogen receptor (ER)-positive tumors irrespective of age, menopausal status, nodal status, or tumor size. Optimal duration of tamoxifen therapy is about 5 years. Future research directions include evaluating the benefit of extending tamoxifen beyond 5 years, the contribution of ovarian ablation, and the role of hormonal manipulations involving selective ER modulators and aromatase inhibitors instead of or in addition to tamoxifen. In the area of adjuvant chemotherapy, polychemotherapy regimens have been consistently found to be superior to single agents, and anthracycline-containing regimens produce a small but statistically significant improvement in survival when compared with regimens not containing an anthracycline. High-dose adjuvant chemotherapy with stem cell support has not been proven superior to standard regimens. Neoadjuvant therapy offers the possibility of testing in vivo the sensitivity of individual tumors to particular cytotoxic regimens and, hence, of improving ultimate disease control, as well as reducing the extent of local therapy. The contribution and optimal integration of taxanes in the adjuvant setting are yet to be established but are the subject of intense research effort. Similarly, novel targeted therapies such as trastuzumab and bisphosphonates are currently being evaluated in adjuvant studies
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3816/cbc.2001.s.004" target="_blank" rel="noreferrer noopener">10.3816/cbc.2001.s.004</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2001
Adjuvant
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy/surgery
Chemotherapy
Clinical breast cancer
Clinical Trials as Topic
Decision Making
Diphosphonates/therapeutic use
Female
Hormonal/*therapeutic use
Humans
Mamounas E P
Neoadjuvant Therapy
Ovary/drug effects/physiology
Prognosis
Tamoxifen/administration & dosage
Taxoids/therapeutic use